Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intuor Technologies, Inc.
• Treatments: Nepafenac; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens.

Exclusion Criteria:

• previous uveitis (<1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs